TRANSCRANIAL MAGNETIC STIMULATOR MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Transcranial Magnetic Stimulator Market, By Type (Deep Transcranial Magnetic Stimulator, Repetitive Transcranial Magnetic Stimulator, and Others), By Application (Depression Treatment, Tinnitus Treatment, Alzheimer’s Disease Treatment, Epilepsy Treatment, Stroke Rehabilitation, Parkinson’s Disease Treatment, and Others), By Frequency (Low-frequency RTMS and High-frequency RTMS), By End-User (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East)

Recent Developments

New product launches

On April 17, 2023, Nexstim Plc., a globally operating growth-oriented medical technology company, announced the launch of NBS 6, a new navigated transcranial magnetic stimulation (nTMS) system software generation, in the U.S.
On March 21, 2023, MagVenture A/S, a market-leading manufacturer of non-invasive Transcranial Magnetic Stimulation (TMS) systems, received the U.S. Food and Drug Administration (FDA) clearance for MagVenture TMS Atlas Neuro Navigation System, which is a time-saving coil positioning system for the clinical application of Transcranial Magnetic Stimulation (TMS)
In October 2021, Neuronetics, Inc., a commercial-stage medical technology company, announced the release of the latest evolution of its NeuroStar Advanced Therapy system with upgraded equipment and features
In May 2021, Nexstim Plc., a globally operating growth-oriented medical technology company, announced that it has received authorization for the distribution of its NBS system by the Australian Therapeutic Goods Administration (TGA). The medical device license allows the company to start marketing and selling NBS systems in Australia to be used for neurosurgical applications.

Acquisitions and partnerships

In July 2022, Greenbrook TMS Inc., a leading provider of Transcranial Magnetic Stimulation (TMS) therapy, announced the acquisition of Check Five LLC, a liability company, to further expand future treatment modalities and indications
In February 2022, Nexstim Plc, a globally operating growth-oriented medical technology company, announced it has signed an agreement to license technology it has developed to Magnus Medical, Inc., a U.S.-based medical technology company. The technology to be licensed is related to the NBT system developed by the company with certain restrictions and the related patents, and the use of the license is restricted to the treatment of neuropsychiatric disorders. Nexstim e-field modelling and application software are not included in the license.
In July 2020, Magstim, the global leader in Transcranial Magnetic Stimulation (TMS), announced the acquisition of the product portfolio of Electrical Geodesics, Inc. (EGI), a global leader in health technology. EGI designs non-invasive multimodal technologies to monitor brain activity and deliver transcranial electrical stimulation in brain research. Magstim will acquire EGI hardware, software, and sensor nets assets and will immediately manage global sales, service, and support.